Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $21.87 USD
Change Today -0.87 / -3.83%
Volume 119.7K
CHRS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:55 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

coherus biosciences inc (CHRS) Snapshot

Open
$23.02
Previous Close
$22.74
Day High
$23.36
Day Low
$21.43
52 Week High
03/3/15 - $33.30
52 Week Low
11/6/14 - $12.27
Market Cap
825.7M
Average Volume 10 Days
193.8K
EPS TTM
--
Shares Outstanding
37.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COHERUS BIOSCIENCES INC (CHRS)

Related News

No related news articles were found.

coherus biosciences inc (CHRS) Related Businessweek News

No Related Businessweek News Found

coherus biosciences inc (CHRS) Details

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

66 Employees
Last Reported Date: 03/23/15
Founded in 2010

coherus biosciences inc (CHRS) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $450.2K
Chief Financial Officer
Total Annual Compensation: $102.4K
Chief Medical Officer
Total Annual Compensation: $443.0K
Chief Scientific Officer
Total Annual Compensation: $352.2K
Compensation as of Fiscal Year 2014.

coherus biosciences inc (CHRS) Key Developments

Coherus Biosciences, Inc. Obtains Positive Results of Repeat Phase 1 Pharmacokinetic (PK) Bioequivalence Study for CHS-0214

Coherus Biosciences, Inc. obtained positive results of a repeat Phase 1 pharmacokinetic (PK) bioequivalence study for CHS-0214, its etanercept (Enbrel) biosimilar candidate. This study was initiated due to the change in the manufacturing location from the United States to the European Union of its CHS-0214 biosimilar candidate, and compared the E.U. produced CHS-0214 to a lot of Enbrel manufactured in Europe. The design of this trial was a single-dose, cross-over study that enrolled 53 healthy volunteers, of which 44 completed the study. The study met all bioequivalence criteria, as the 90% confidence intervals of the ratio for all parameters (maximum serum concentration (C), area under the time-concentration curve from first to last time point measured (AUC), and area under the time-concentration curve from first time point to infinity (AUC 0-inf)) fall fully within the bioequivalence boundaries of 80-125%.

Coherus BioSciences and Baxter International Amend CHS-0214 Collaboration Agreement

Coherus BioSciences and Baxter International have made amendments to certain financial terms of their collaboration agreement that was signed to develop and commercialise CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets. Both firms signed the contract in August 2013. Under the amended contract, certain existing milestones and funding obligations have been revised, and the deal has been expanded to include select pre-commercialisation activities. The received milestone payments are likely to exceed the earlier Baxter funding obligations by around USD 12 million.

Coherus Biosciences, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Fiscal Year Ended December 31, 2014

Coherus Biosciences, Inc. reported unaudited consolidated earnings results for the fourth quarter and fiscal year ended December 31, 2014. For the quarter, the company reported total revenue for the fourth quarter 2014 was $6.5 million, as compared to $1.2 million in the fourth quarter of 2013. The increase over the same period in 2013 was due to the recognition of Baxter collaboration revenue. Net loss attributable to the company was $29.1 million, or $1.47 per basic and diluted share, compared to $14.6 million, or $3.68 per basic and diluted share, for the same period in 2013. Loss from operations was $26.560 million against $10.487 million a year ago. For the year, the company’s total revenue was $31.1 million, as compared to $2.8 million in 2013. The increase over the same period in 2013 was due to the recognition of Baxter collaboration revenue. Net loss attributable to the company was $87.1 million, or $10.64 per basic and diluted share, compared to $53.6 million, or $16.10 per basic and diluted share, in 2013. Loss from operations was $64.682 million against $35.993 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHRS:US $21.87 USD -0.87

CHRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CHRS.
View Industry Companies
 

Industry Analysis

CHRS

Industry Average

Valuation CHRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.0x
Price/Book 11.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COHERUS BIOSCIENCES INC, please visit www.coherus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.